Ondansetron for Indigestion in Diabetics

Recruiting in Palo Alto (17 mi)

Overseen by Adil Bharucha, MBBS, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Mayo Clinic

Must not be taking: Opiates, MAO inhibitors, GLP-1 agonists, others

Disqualifiers: Cardiovascular, Renal, Hepatic, Neurological, others

Prior Safety Data

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial aims to understand why people with indigestion and diabetes have stomach issues. Researchers will study ondansetron, a medication that prevents nausea, to see its effects on these symptoms. Ondansetron is commonly used to prevent nausea and vomiting, particularly in patients undergoing chemotherapy. The study will look at how ondansetron affects stomach function during different tests and in daily life.

Will I have to stop taking my current medications?

The trial requires stopping certain medications like opiates, alpha adrenergic agonists, metoclopramide, monoamine oxidase inhibitors, more than one serotonergic medication, and high doses of anticholinergic agents if it's medically safe. These should be discontinued for a period of four half-lives before the study assessments.

Is ondansetron safe for humans?

Ondansetron, also known as Zofran, has been used safely in many patients, including those undergoing cancer treatment. Common side effects are headache and constipation, but serious side effects are rare. It has not been linked to birth defects and is generally well tolerated. ^{1 2 3 4 5}

How does the drug ondansetron differ from other treatments for indigestion in diabetics?

Ondansetron is unique because it is a 5-HT3 receptor antagonist, originally used to prevent nausea and vomiting caused by chemotherapy, which may offer a novel approach for treating indigestion in diabetics by targeting serotonin pathways involved in gastrointestinal function. ^{1 2 6 7 8}

Research Team

Adil Bharucha, MBBS, MD

Principal Investigator

Mayo Clinic

Eligibility Criteria

This trial is for adults aged 18-75 with diabetes (Type 1 or Type 2) and indigestion symptoms that started or worsened after their diabetes diagnosis. Participants must be able to eat test meals and not be pregnant, breastfeeding, or have a structural cause for symptoms. Those with significant health issues, certain heart conditions, allergies to eggs, or on specific medications are excluded.

Inclusion Criteria

I have had diabetes for over 3 years and my stomach discomfort started or got worse after my diagnosis.

Able to communicate adequately with the investigator and to comply with the requirements for the entire study, including the willingness and ability to consume the components of the test meals

I am a healthy male or a female not pregnant or breastfeeding.

Exclusion Criteria

I am experiencing symptoms of a stomach or bowel problem.

I am not currently using certain medications or can stop them safely before the study.

I have not had major abdominal surgery, except for minor procedures like appendectomy.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either Ondansetron or placebo during gastric emptying and duodenal infusion, followed by oral administration three times a day for weeks 3-6

6 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Ondansetron (5-HT3 Receptor Antagonist)
• Placebo (Other)

Trial Overview The study tests the effects of Ondansetron (8mg), an anti-nausea medication, against a placebo in managing gastrointestinal discomfort in people with both indigestion and diabetes. It aims to understand if this drug can reduce sensitivity to nutrients causing these symptoms.

Participant Groups

Group I: Non-ulcer dyspepsia (NUD) Ondansetron 8 mg Experimental Treatment 1 Intervention

Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion. Oral Ondansetron 8 mg administered three times a day for weeks 3-6

Group II: Healthy Control Ondansetron 8 mg Experimental Treatment 1 Intervention

Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.

Group III: Diabetic (DM) gastroenteropathy Ondansetron 8 mg Experimental Treatment 1 Intervention

Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion. Oral Ondansetron 8 mg administered three times a day for weeks 3-6

Group IV: Diabetic (DM) gastroenteropathy Placebo Placebo Group 1 Intervention

Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion. Oral matched placebo administered three times a day for weeks 3-6

Group V: Healthy Control Placebo Placebo Group 1 Intervention

Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.

Group VI: Non-ulcer dyspepsia (NUD) Placebo Placebo Group 1 Intervention

Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion. Oral matched placebo administered three times a day for weeks 3-6

Ondansetron is already approved in Canada for the following indications:

Approved in Canada as Zofran for:

• Prevention of nausea and vomiting associated with chemotherapy
• Prevention of postoperative nausea and vomiting

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials

3,427

Recruited

3,221,000+

Dr. Gianrico Farrugia

Mayo Clinic

Chief Executive Officer since 2019

MD from University of Malta Medical School

Dr. Richard Afable

Mayo Clinic

Chief Medical Officer

MD from Loyola Stritch School of Medicine

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Trials

2,513

Recruited

4,366,000+

Dr. Griffin P. Rodgers

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Chief Executive Officer since 2007

MD, M.A.C.P.

Dr. Griffin P. Rodgers

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Chief Medical Officer since 2007

MD, M.A.C.P.

Findings from Research

In a study of 35 children undergoing highly emetogenic chemotherapy, ondansetron was found to be highly effective in preventing nausea and vomiting, achieving complete or major responses in 85.3% of patients without cisplatin and 71.4% with cisplatin, compared to only 38.8% with traditional antiemetics.

Ondansetron was administered at lower than recommended doses for 85 days without any adverse effects, indicating it is a safe and effective antiemetic option, especially since it does not cause sedation and was well-received by patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Ondansetron as an effective drug in prophylaxis of chemotherapy--induced emesis in children. Kołecki, P., Wachowiak, J., Beshari, SE.[2013]

Ondansetron effectively controlled acute emesis in 53% of patients on a specific dosing schedule after non-cisplatin-based chemotherapy, demonstrating its potential as a treatment for those previously resistant to standard antiemetics.

The drug maintained its antiemetic efficacy across multiple treatment cycles, with no major toxicity reported, making it a safe option for patients experiencing chemotherapy-induced nausea and vomiting.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy. Seynaeve, C., de Mulder, PH., Lane-Allman, E., et al.[2019]

In a study involving 36 patients undergoing chemotherapy with cisplatin, fast dissolving ondansetron (Zofran Zydis) demonstrated a 75% complete response rate in preventing nausea and vomiting.

This new formulation is particularly beneficial for patients who have difficulty swallowing traditional oral antiemetics, making it an effective addition to antiemetic treatments for chemotherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Freeze dried ondansetron: first observations with the fast dissolving oral antiemetic Zofran Zydis for the prophylaxis of the cisplatin-induced emesis in gynecological cancer patients. Lehoczky, O., Udvary, J., Pulay, T.[2013]

A recent study found no evidence that the anti-nausea drug Zofran (ondansetron) increases the risk of birth defects in children.

This finding suggests that Zofran can be considered safe for use during pregnancy regarding concerns about congenital anomalies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Morning sickness drug is not linked to increased risk of birth defects. [2017]

Ondansetron has been shown to be safe and well-tolerated in approximately 1,400 cancer patients and 650 other volunteers, with the main side effects being mild constipation and headache.

The drug has a wide therapeutic index, does not interact with commonly prescribed medications, and has no reported dependence or extrapyramidal side effects, making it a reliable option for anti-emetic treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety of ondansetron. Smith, RN.[2013]

In a study of 28 cancer patients, ondansetron significantly reduced nausea and vomiting caused by cisplatin treatment, with the median time to the first vomiting episode extending from 2.8 hours in the placebo group to 11.6 hours in the ondansetron group.

Ondansetron was found to be safe, with no adverse effects reported, and it effectively eliminated the need for additional antiemetic treatments in patients, demonstrating its efficacy as a serotonin S3 receptor antagonist.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. Cubeddu, LX., Hoffmann, IS., Fuenmayor, NT., et al.[2013]

In a phase II study involving 25 patients undergoing cisplatin chemotherapy, ondansetron effectively controlled nausea and vomiting, achieving 'good' control rates of 64-100% for vomiting and 88-100% for nausea.

Ondansetron was well tolerated with minimal side effects, indicating it is a safe option for preventing chemotherapy-induced nausea and vomiting, although further randomized studies are recommended for comparison with standard anti-emetics.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Use of oral and intravenous ondansetron in patients treated with cisplatin. Khoo, KS., Ang, PT., Soh, LT., et al.[2020]

In a study of 40 patients with advanced tumors receiving various chemotherapy regimens, ondansetron demonstrated a strong prophylactic antiemetic effect, particularly in the CHOP group, where 64% experienced full control of nausea and vomiting.

No significant side effects were reported from ondansetron treatment, indicating it is a safe option for managing chemotherapy-induced nausea and loss of appetite in cancer patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting]. Gershanovich, ML., Beresneva, IA., Makhnova, EV.[2015]

References

1. Poland pubmed.ncbi.nlm.nih.gov

Ondansetron as an effective drug in prophylaxis of chemotherapy--induced emesis in children. [2013]

2. England pubmed.ncbi.nlm.nih.gov

The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy. [2019]

3. Slovakia pubmed.ncbi.nlm.nih.gov

Freeze dried ondansetron: first observations with the fast dissolving oral antiemetic Zofran Zydis for the prophylaxis of the cisplatin-induced emesis in gynecological cancer patients. [2013]

4. England pubmed.ncbi.nlm.nih.gov

Morning sickness drug is not linked to increased risk of birth defects. [2017]

5. England pubmed.ncbi.nlm.nih.gov

Safety of ondansetron. [2013]

6. United States pubmed.ncbi.nlm.nih.gov

Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. [2013]

7. Singapore pubmed.ncbi.nlm.nih.gov

Use of oral and intravenous ondansetron in patients treated with cisplatin. [2020]

8. Russia (Federation) pubmed.ncbi.nlm.nih.gov

[Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting]. [2015]